GERMANTOWN,
Md., April 24, 2024 /PRNewswire/ -- Precigen,
Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing
in the development of innovative gene and cell therapies to improve
the lives of patients, today announced clinical data from the
pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy for the
treatment of patients with recurrent respiratory papillomatosis
(RRP) will be presented in a late-breaking oral presentation at the
2024 American Society of Clinical Oncology (ASCO) Annual Meeting
taking place from May 31 to June 4,
2024 at McCormick Place in Chicago, Illinois.
Abstract
Title
|
Abstract
#
|
Presentation
Details
|
PRGN-2012, a novel
gorilla adenovirus-based immunotherapy, provides
the first treatment that leads to complete and durable
responses in
recurrent respiratory papillomatosis patients
|
LBA6015
|
Session Title:
Rapid Oral Abstract Session –
Head and Neck Cancer
Session Date and
Time: June 3,
2024 8:00 AM - 9:30 AM
CT
|
Event details are available on Precigen's website
in the Events & Presentations section at
investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with
Precision™
Precigen (Nasdaq: PGEN) is a dedicated
discovery and clinical stage biopharmaceutical company advancing
the next generation of gene and cell therapies using precision
technology to target the most urgent and intractable diseases in
our core therapeutic areas of immuno-oncology, autoimmune
disorders, and infectious diseases. Our technologies enable us to
find innovative solutions for affordable biotherapeutics in a
controlled manner. Precigen operates as an innovation engine
progressing a preclinical and clinical pipeline of
well-differentiated therapies toward clinical proof-of-concept and
commercialization. For more information about Precigen, visit
www.precigen.com or follow us on X @Precigen, LinkedIn or
YouTube.
AdenoVerse™
Immunotherapy
Precigen's AdenoVerse immunotherapy platform
utilizes a library of proprietary adenovectors for the efficient
gene delivery of therapeutic effectors, immunomodulators, and
vaccine antigens designed to modulate the immune system. Precigen's
gorilla adenovectors, part of the AdenoVerse library, have
potentially superior performance characteristics as compared to
current competition. AdenoVerse immunotherapies have been shown to
generate high-level and durable antigen-specific T-cell immune
responses as well as an ability to boost these responses via repeat
administration. Superior performance characteristics and high yield
manufacturing of AdenoVerse vectors leveraging
UltraVector® technology allows Precigen to engineer
cutting-edge investigational gene therapies to treat complex
diseases.
AdenoVerse™ Immunotherapy Clinical
Programs
Precigen's AdenoVerse immunotherapy platform is
currently under clinical investigation in a Phase 1/2 study of
PRGN-2009 alone or in combination with an anti-PDL1/TGF-Beta
Trap in patients with HPV-associated cancers (NCT04432597), a Phase
2 study of PRGN-2009 in combination with pembrolizumab in newly
diagnosed patients with HPV-associated oropharyngeal squamous cell
carcinoma (OPSCC) (NCT05996523), a Phase 2 study of
PRGN-2009 in combination with pembrolizumab in patients with
recurrent or metastatic cervical cancer (NCT06157151), and a Phase
1/2 study of PRGN-2012 in patients with recurrent respiratory
papillomatosis (RRP) (NCT04724980). PRGN-2012 has been
granted Orphan Drug Designation and Breakthrough Therapy
Designation in patients with RRP by the FDA and Orphan Drug
Designation by the European Commission.
Trademarks
Precigen, AdenoVerse,
UltraVector and Advancing Medicine with Precision are trademarks
of Precigen and/or its affiliates. Other names may be
trademarks of their respective owners.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press release
are forward-looking statements. These forward-looking statements
are based upon the Company's current expectations and projections
about future events and generally relate to plans, objectives, and
expectations for the development of the Company's business,
including the timing and progress of preclinical studies, clinical
trials, discovery programs and related milestones, the promise of
the Company's portfolio of therapies, and in particular its CAR-T
and AdenoVerse therapies. Although management believes that the
plans and objectives reflected in or suggested by these
forward-looking statements are reasonable, all forward-looking
statements involve risks and uncertainties and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release. The Company has no
obligation to provide any updates to these forward-looking
statements even if its expectations change. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. For further information on potential risks
and uncertainties, and other important factors, any of which could
cause the Company's actual results to differ from those contained
in the forward-looking statements, see the section entitled "Risk
Factors" in the Company's most recent Annual Report on Form 10-K
and subsequent reports filed with the Securities and Exchange
Commission.
Investor Contact:
Steven M.
Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M.
Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-to-present-late-breaking-abstract-for-pivotal-phase-2-study-data-for-prgn-2012-adenoverse-immunotherapy-for-the-treatment-of-patients-with-recurrent-respiratory-papillomatosis-at-the-2024-asco-annual-meeting-302125357.html
SOURCE Precigen, Inc.